Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Short-term Investments (2016 - 2025)

Capricor Therapeutics (CAPR) has 12 years of Short-term Investments data on record, last reported at $79.1 million in Q3 2025.

  • For Q3 2025, Short-term Investments rose 374.77% year-over-year to $79.1 million; the TTM value through Sep 2025 reached $79.1 million, up 374.77%, while the annual FY2024 figure was $140.2 million, 465.6% up from the prior year.
  • Short-term Investments reached $79.1 million in Q3 2025 per CAPR's latest filing, down from $99.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $140.2 million in Q4 2024 and bottomed at $16.7 million in Q3 2024.
  • Average Short-term Investments over 4 years is $51.1 million, with a median of $34.1 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: tumbled 48.86% in 2023, then surged 465.6% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $31.8 million in 2022, then decreased by 22.08% to $24.8 million in 2023, then soared by 465.6% to $140.2 million in 2024, then crashed by 43.62% to $79.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $79.1 million in Q3 2025, $99.6 million in Q2 2025, and $116.0 million in Q1 2025.